Table. 1.

Table. 1.

Isolated breast relapse of acute lymphoblastic leukemia after allogeneic HSCT: review of pediatric cases

Author [Ref] Initial diagnosis of ALL Breast relapse
Type Age (years) WBC(/µL) Karyotype EMD Disease status at HSCT Graft TBI Acute GvHD Age at relapse (years) Time to breast relapse after HSCT (months) Location Treatment Outcome
Conter [3] B-ALL 10 NA 46,XX N CR2 BM Y Y 16 8 Unilateral CTx+RT 2nd iEMR (CNS) after CR in 9 months
Savasan [4] B-ALL 15 8,000 46,XX N CR1a) BM Y Y 16 12 Unilateral 1st iEMR: CTx
2nd iEMR: CTx+RT
on maintenance CTx
Howrey [5] T-ALL 12 2,600 complex N CR2 UCB Y Y 15 12 Unilateral RT (palliative) DOD (BM relapse)
Kumar [6] B-ALL 6 NA NA NA CR3 UCB Y NA 13 15 Unilateral CTx+2nd HSCT NA
Houghtelin [7] B-ALL 18 NA complex N CR1b) PB Y N 20 32 Bilateral CTx+2nd HSCT CR in 44 months
Our case ETP-ALL 12 124,200 complex N CR1 PB Y N 14 12 Unilateral CTx+RT on maintenance CTx

a)CR was achieved following two courses of high-dose Ara-C and L-asparaginase after induction failure with the three-drug induction therapy. b)By the decision of medical oncologists. Ref, reference; B-ALL, B-cell precursor acute lymphoblastic leukemia; T-ALL, T-cell acute lymphoblastic leukemia; ETP-ALL, early T-cell precursor acute lymphoblastic leukemia; EMD, extramedullary disease; HSCT, hematopoietic stem cell transplantation; CR, complete remission; BM, bone marrow; UCB, umbilical cord blood; PB, peripheral blood; TBI, total body irradiation; GvHD, graft-versus-host disease; CTx, chemotherapy; RT, radiotherapy; iEMR, isolated extramedullary relapse; CNS, central nervous system; DOD, died of disease; Y, yes; N, no; NA, not available.

Clin Pediatr Hematol Oncol 2022;29:30-4
© 2022 Clin Pediatr Hematol Oncol